Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

This report by a group of UK retina specialists and health professionals considers best
practice recommendations for the management of sight-threatening neovascular age-related …

Importance Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in
Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and …

Purpose To compare identification rates of retinal fluid of the Notal Vision Home Optical
Coherence Tomography (OCT) device (NVHO) when used by people with age-related …

Objectives This report aims to provide clear recommendations and practical guidance from a
panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be …

To assess predictors of treatment response in neovascular age‐related macular
degeneration (AMD) in an attempt to develop a patient‐centric treatment algorithm. We …

Importance Although multiple imputation models for missing data and the use of mixed-
effects models generally provide better outcome estimates than using only observed data or …

Objective To evaluate treatment patterns and outcomes of patients in the United States who
received antivascular endothelial growth factor (anti-VEGF) agents for wet age-related …

Despite significant progress in retaining vision for neovascular age-related macular
degeneration patients in the era of treatment with intravitreal anti-VEGF agents, there is no …

Purpose To investigate the relationship between retinal fluid and vision in ranibizumab-
treated patients with neovascular age-related macular degeneration (nAMD). Design …